Antibody-Dependent Cellular Cytotoxicity (ADCC)

Antibody Fc: Linking Adaptive and Innate Immunity

Volumn , Issue , 2013, Pages 1-27

  Gómez Román, Victor Raúl ^a   Murray, Joseph C ^b   Weiner, Louis M ^b  

^a International Vaccine Institute   (South Korea)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

ADCC; Antibodies; Cancer; Infectious disease; Monoclonal antibodies; NK cells

Indexed keywords

EID: 84902418508     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-394802-1.00001-7     Document Type: Chapter

References (131)

1. Möeller E Contact-induced cytotoxicity by lymphoid cells containing foreign isoantigens. Science 1965, 147(3660):873-879.
2. MacLennan IC, Loewi G, Harding B The role of immunoglobulins in lymphocyte-mediated cell damage, in vitro. I. Comparison of the effects of target cell specific antibody and normal serum factors on cellular damage by immune and non-immune lymphocytes. Immunology 1970, 18(3):397-404.
3. Pudifin DJ, Harding B, MacLennan IC The differential effect of gamma irradiation on the sensitizing and effector stages of antibody dependent lymphocyte mediated cytotoxicity. Immunology 1971, 21(5):853-860.
4. Wallace PK, Howell AL, Fanger MW Role of Fc gamma receptors in cancer and infectious disease. J Leukocyte Biol 1994, 55(6):816-826.
5. Tudor D, Bomsel M The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcgammaRI-dependent manner. Aids 2011, 25(6):751-759.
6. Horner H, Frank C, Dechant C, et al. Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity. J Immunol 2007, 179(1):337-345.
7. Shen R, Richter HE, Clements RH, et al. Macrophages in vaginal but not intestinal mucosa are monocyte-like and permissive to human immunodeficiency virus type 1 infection. J Virol 2009, 83(7):3258-3267.
8. Kato K, Fridman WH, Arata Y, Sautes-Fridman C A conformational change in the Fc precludes the binding of two Fcgamma receptor molecules to one IgG. Immunol Today 2000, 21(7):310-312.
9. Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002, 277(30):26733-26740.
10. Ferrara C, Grau S, Jager C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci USA 2011, 108(31):12669-12674.
11. Liao F, Shin HS, Rhee SG Cross-linking of Fc gamma RIIIA on natural killer cells results in tyrosine phosphorylation of PLC-gamma 1 and PLC-gamma 2. J Immunol 1993, 150(7):2668-2674.
12. Saxena RK, Saxena QB, Adler WH Identity of effector cells participating in the reverse antibody-dependent cell-mediated cytotoxicity. Immunology 1982, 46(2):459-464.
13. Leibson PJ Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity 1997, 6(6):655-661.
14. Sanchez-Mejorada G, Rosales C Signal transduction by immunoglobulin Fc receptors. J Leukocyte Biol 1998, 63(5):521-533.
15. Zompi S, Colucci F Anatomy of a murder-signal transduction pathways leading to activation of natural killer cells. Immunol Lett 2005, 97(1):31-39.
16. Procopio AD, Paolini R, Vecchio I, Frati L, Santoni A GTP-binding proteins transduce signals generated via human FC gamma receptor IIIA (CD16). J Immunol 1991, 146(10):3550-3556.
17. Ortiz-Stern A, Rosales C Cross-talk between Fc receptors and integrins. Immunol Lett 2003, 90(2-3):137-143.
18. Karsten CM, Pandey MK, Figge J, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med 2012, 18(9):1401-1406.
19. Galandrini R, Tassi I, Mattia G, et al. SH2-containing inositol phosphatase (SHIP-1) transiently translocates to raft domains and modulates CD16-mediated cytotoxicity in human NK cells. Blood 2002, 100(13):4581-4589.
20. Lichtfuss GF, Meehan AC, Cheng WJ, et al. HIV inhibits early signal transduction events triggered by CD16 cross-linking on NK cells, which are important for antibody-dependent cellular cytotoxicity. J Leukocyte Biol 2011, 89(1):149-158.
21. Wood SM, Meeths M, Chiang SC, et al. Different NK cell-activating receptors preferentially recruit Rab27a or Munc13-4 to perforin-containing granules for cytotoxicity. Blood 2009, 114(19):4117-4127.
22. Trapani JA, Smyth MJ Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002, 2(10):735-747.
23. Smyth MJ, Kelly JM, Sutton VR, et al. Unlocking the secrets of cytotoxic granule proteins. J Leukocyte Biol 2001, 70(1):18-29.
24. Berthou C, Bourge JF, Zhang Y, et al. Interferon-gamma-induced membrane PAF-receptor expression confers tumor cell susceptibility to NK perforin-dependent lysis. Blood 2000, 95(7):2329-2336.
25. Eischen CM, Schilling JD, Lynch DH, Krammer PH, Leibson PJ Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 1996, 156(8):2693-2699.
26. Boyle JJ Human macrophages kill human mesangial cells by Fas-L-induced apoptosis when triggered by antibody via CD16. Clin Exp Immunol 2004, 137(3):529-537.
27. Koller CA, LoBuglio AF Monocyte-mediated antibody-dependent cell-mediated cytotoxicity: the role of the metabolic burst. Blood 1981, 58(2):293-299.
28. Bruchelt G, Handgretinger R, Fierlbeck G, et al. Lysis of neuroblastoma cells by the ADCC-reaction: granulocytes of patients with chronic granulomatous disease are more effective than those of healthy donors. Immunol Lett 1989, 22(3):217-220.
29. Golub RM, Descamps-Latscha B Role of oxygen-dependent mechanisms in monoclonal antibody-induced lysis of normal T cells by phagocytes. I. Human phagocytes. Ann Inst Pasteur Immunol 1985, 136D(1):3-18.
30. Boross P, Jansen JH, Pastula A, van der Poel CE, Leusen JH Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice. Immunol Lett 2012, 143(1):44-52.
31. Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, et al. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 2008, 112(6):2390-2399.
32. Timonen T, Saksela E A simplified isotope release assay for cell-mediated cytotoxicity against anchorage dependent target cells. J Immunol Meth 1977, 18(1-2):123-132.
33. Kato K, Agatsuma T, Tanabe T, Masuko T, Hashimoto Y Release of esterase from murine lymphokine-activated killer cells in antibody-dependent cellular cytotoxic reaction. Jpn J Cancer Res (Gann) 1991, 82(2):206-212.
34. Ortaldo JR, Winkler-Pickett RT, Nagashima K, Yagita H, Okumura K Direct evidence for release of pore-forming protein during NK cellular lysis. J Leukocyte Biol 1992, 52(5):483-488.
35. Jacobs DB, Pipho C Use of propidium iodide staining and flow cytometry to measure anti-mediated cytotoxicity: resolution of complement-sensitive and resistant target cells. J Immunol Meth 1983, 62(1):101-108.
36. Lee-MacAry AE, Ross EL, Davies D, et al. Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodide. J Immunol Meth 2001, 252(1-2):83-92.
37. Gomez-Roman VR, Florese RH, Patterson LJ, et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Meth 2006, 308(1-2):53-67.
38. Pollara J, Hart L, Brewer F, et al. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A J Int Soc Analyt Cytol 2011, 79(8):603-612.
39. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997, 15(10):3266-3274.
40. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996, 14(3):737-744.
41. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med 2004, 351(4):337-345.
42. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New Engl J Med 2006, 354(6):567-578.
43. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007, 25(16):2171-2177.
44. Fan Z, Masui H, Altas I, Mendelsohn J Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993, 53(18):4322-4328.
45. Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007, 13(5):1552-1561.
46. Riechmann L, Clark M, Waldmann H, Winter G Reshaping human antibodies for therapy. Nature 1988, 332(6162):323-327.
47. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010, 184(1):512-520.
48. Clynes RA, Towers TL, Presta LG, Ravetch JV Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000, 6(4):443-446.
49. de Haij S, Jansen JH, Boross P, et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 2010, 70(8):3209-3217.
50. Minard-Colin V, Xiu Y, Poe JC, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 2008, 112(4):1205-1213.
51. Hubert P, Heitzmann A, Viel S, et al. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res 2011, 71(15):5134-5143.
52. Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004, 10(17):5650-5655.
53. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004, 64(13):4664-4669.
54. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99(3):754-758.
55. Weng WK, Levy R Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21(21):3940-3947.
56. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26(11):1789-1796.
57. Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007, 25(24):3712-3718.
58. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009, 27(7):1122-1129.
59. Veeramani S, Wang SY, Dahle C, et al. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 2011, 118(12):3347-3349.
60. Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Brit J Cancer 2006, 94(2):259-267.
61. Assaad F, Bektimirov T, Ennis F, et al. Immune responses to viral antigens in man and their relevance to vaccine development: memorandum from a WHO meeting. Bull WHO 1983, 61(6):935-940.
62. Balachandran N, Bacchetti S, Rawls WE Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect Immun 1982, 37(3):1132-1137.
63. Ahmad R, Sindhu ST, Toma E, et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol 2001, 21(3):227-233.
64. Forthal DN, Landucci G, Keenan B Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+lymphocyte count. AIDS Res Hum Retroviruses 2001, 17(6):553-561.
65. Banks ND, Kinsey N, Clements J, Hildreth JE Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses 2002, 18(16):1197-1205.
66. Gomez-Roman VR, Patterson LJ, Venzon D, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005, 174(4):2185-2189.
67. Hidajat R, Xiao P, Zhou Q, et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 2009, 83(2):791-801.
68. Florese RH, Demberg T, Xiao P, et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 2009, 182(6):3718-3727.
69. Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. Aids 2009, 23(8):897-906.
70. Xiao P, Zhao J, Patterson LJ, et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2010, 84(14):7161-7173.
71. Sun Y, Asmal M, Lane S, et al. Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J Virol 2011, 85(14):6906-6912.
72. Xiao P, Patterson LJ, Kuate S, et al. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J Virol 2012, 86(8):4644-4657.
73. Haase AT Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010, 464(7286):217-223.
74. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. New Engl J Med 2009, 361(23):2209-2220.
75. Karnasuta C, Paris RM, Cox JH, et al. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005, 23(19):2522-2529.
76. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. New Engl J Med 2012, 366(14):1275-1286.
77. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449(7158):101-104.
78. Moldt B, Shibata-Koyama M, Rakasz EG, et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 2012, 86(11):6189-6196.
79. Zalevsky J, Leung IW, Karki S, et al. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 2009, 113(16):3735-3743.
80. Junttila TT, Parsons K, Olsson C, et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 2010, 70(11):4481-4489.
81. Jefferis R Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Disc 2009, 8(3):226-234.
82. Jiang XR, Song A, Bergelson S, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Disc 2011, 10(2):101-111.
83. Idusogie EE, Wong PY, Presta LG, et al. Engineered antibodies with increased activity to recruit complement. J Immunol 2001, 166(4):2571-2575.
84. Iida S, Misaka H, Inoue M, et al. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res 2006, 12(9):2879-2887.
85. Suzuki E, Niwa R, Saji S, et al. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin Cancer Res 2007, 13(6):1875-1882.
86. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001, 276(9):6591-6604.
87. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006, 103(11):4005-4010.
88. Radaev S, Sun P Recognition of immunoglobulins by Fcgamma receptors. Molec Immunol 2002, 38(14):1073-1083.
89. Suzuki T, Ishii-Watabe A, Tada M, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010, 184(4):1968-1976.
90. Yeung YA, Leabman MK, Marvin JS, et al. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009, 182(12):7663-7671.
91. Sehn LH, Assouline SE, Stewart DA, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012, 119(22):5118-5125.
92. Forero-Torres A, de Vos S, Pohlman BL, et al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res 2012, 18(5):1395-1403.
93. Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 2004, 279(52):53907-53914.
94. Nelson AL, Reichert JM Development trends for therapeutic antibody fragments. Nat Biotechnol 2009, 27(4):331-337.
95. Hudson PJ, Souriau C Engineered antibodies. Nat Med 2003, 9(1):129-134.
96. Beck A, Wurch T, Bailly C, Corvaia N Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010, 10(5):345-352.
97. Wang J, Balog CI, Stavenhagen K, et al. Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Molec Cell Proteomics 2011, 10(5). M110 004655.
98. Guo N, Liu Y, Masuda Y, et al. Repeated immunization induces the increase in fucose content on antigen-specific IgG N-linked oligosaccharides. Clin Biochem 2005, 38(2):149-153.
99. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002, 195(1):125-133.
100. Harbers SO, Crocker A, Catalano G, et al. Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 2007, 117(5):1361-1369.
101. Wilson NS, Yang B, Yang A, et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011, 19(1):101-113.
102. Yang X, Zhang X, Mortenson ED, Radkevich-Brown O, Wang Y, Fu YX Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. Molec Ther 2013, 21(1):91-100.
103. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S Macrophage receptors and immune recognition. Annu Rev Immunol 2005, 23:901-944.
104. Lanier LL Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008, 9(5):495-502.
105. Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010, 142(5):699-713.
106. Kohrt HE, Houot R, Goldstein MJ, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011, 117(8):2423-2432.
107. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001, 19(19):3918-3928.
108. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002, 20(10):2453-2463.
109. Steiner M, Neri D Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res 2011, 17(20):6406-6416.
110. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. New Engl J Med 2010, 363(19):1812-1821.
111. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. New Engl J Med 2012, 367(19):1783-1791.
112. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011, 128(2):347-356.
113. Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009, 27(18):2983-2990.
114. Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol 2008, 180(9):6392-6401.
115. Wolchok JD, Yang AS, Weber JS Immune regulatory antibodies: are they the next advance?. Cancer J 2010, 16(4):311-317.
116. Lipson EJ, Drake CG Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011, 17(22):6958-6962.
117. Benson DM, Hofmeister CC, Padmanabhan S, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012, 120(22):4324-4333.
118. Vey N, Bourhis JH, Boissel N, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012, 120(22):4317-4323.
119. Beck A, Reichert JM Marketing approval of mogamulizumab: a triumph for glyco-engineering. mAbs 2012, 4(4):419-425.
120. Chen Z, Freedman MS Correlation of specialized CD16(+) gammadelta T cells with disease course and severity in multiple sclerosis. J Neuroimmunol 2008, 194(1-2):147-152.
121. Wilkinson RW, Lee-MacAry AE, Davies D, Snary D, Ross EL Antibody-dependent cell-mediated cytotoxicity: a flow cytometry-based assay using fluorophores. J Immunol Meth 2001, 258(1-2):183-191.
122. Seidel MG, Freissmuth M, Pehamberger H, Micksche M Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro: synergism between interleukin (IL)-12 and IL-15 or IL-12 and IL-2. Naunyn Schmiedebergs Arch Pharmacol 1998, 358(3):382-389.
123. Yamashita-Kashima Y, Iijima S, Yorozu K, et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 2011, 17(15):5060-5070.
124. Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol 2009, 182(2):1202-1210.
125. Kohl S, Charlebois ED, Sigouroudinia M, et al. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. J Infect Dis 2000, 181(1):335-339.
126. Hashimoto G, Wright PF, Karzon DT Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J Infect Dis 1983, 148(5):785-794.
127. Jegerlehner A, Schmitz N, Storni T, Bachmann MF Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172(9):5598-5605.
128. Mochizuki Y, de Ming T, Hayashi T, Itoh M, Hotta H, Homma M Protection of mice against Sendai virus pneumonia by non-neutralizing anti-F monoclonal antibodies. Microbiol Immunol 1990, 34(2):171-183.
129. Wardley RC, Norley SG, Wilkinson PJ, Williams S The role of antibody in protection against African swine fever virus. Vet Immunol Immunopathol 1985, 9(3):201-212.
130. Moore T, Ananaba GA, Bolier J, et al. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology 2002, 105(2):213-221.
131. Zhou S, Liu S, Song G, Xu Y, Sun W Protective immunity induced by the full-length cDNA encoding paramyosin of Chinese Schistosoma japonicum. Vaccine 2000, 18(27):3196-3204.